Pasar al contenido principal

Resultados de investigación

Rights
Projectcode
Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
oai:repositoriosaludmadrid.es:20.500.12530/146654
Datos de investigación Set de datos (Dataset)

Niveles de galectina 1 y galectina 9 en enfermedades mediadas por mecanismos inmunes

Levels of galectin 1 and galectin 9 in immune-mediated diseases
  • Valero Martínez, Cristina
  • Pardines Ortiz, Marisa
  • Montes Casado, Nuria
  • Daudén Tello, Esteban
  • Fernández Gutiérrez, Benjamín
  • García Planella, Esther
  • Gomollón Garcia, Fernando
  • Gratacos, Jordi
  • Pérez Venegas, José Javier
  • Julia, Antonio
  • Marsal, Sara
  • Lamana Dominguez, Amalia
  • García de Vicuña Pinedo, Rosario
  • González Alvaro, Isidoro
  • Triguero Martínez, Ana
Galectin-1 and -9 (Gal1/9) are essential mediators of immune-inflammatory responses, which makes these proteins potential biomarkers for immune-mediated diseases (IMIDs), such as rheumatoid arthritis (RA), psoriasis (PS), psoriatic arthritis (PsA), inflammatory bowel disease, and systemic lupus erythematosus (SLE). Our aim was to evaluate plasma Gal1/9 differences between IMID patients and healthy donors (HD). We analyzed 980 plasma samples divided into two analytical cohorts (600 discovery group and 380 validation group). Generalized linear models estimated Gal1/9 levels, adjusting for sex, age, storage time, and plate variability. In the overall IMID group, plasma Gal1 levels were comparable to those of HD, while Gal9 levels were significantly elevated. Levels varied across individual diseases: SLE patients consistently showed the highest Gal1/9 levels compared to both HD and other IMIDs, and RA patients had elevated Gal9 levels versus HD. Both Gal1 and Gal9 plasma levels correlated positively with higher disease activity, and Gal1 was higher in patients with longer disease duration. After adjustment for these confounders, SLE and RA patients maintained the highest Gal9 levels compared to HD. Our study demonstrates that Gal1 and Gal9 are differentially expressed across IMIDs, with particularly elevated levels in SLE, and both galectins are associated with disease activity.
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
oai:repositoriosaludmadrid.es:20.500.12530/146689
Datos de investigación Set de datos (Dataset)

Prognostic value of glycemic variability in acute ischemic stroke in the GLycemia In Acute Stroke (GLIAS) III study. Anonymised Dataset

Elena de Celis Ruiz, Silvia Pastor, Noemí González Pérez de Villar, María Martínez-Balaguer, Marimar Freijo, Mar Castellanos, Noemí Díez-González, María Santamaría, Laura Amaya-Pascasio, Arturo Fraga Bau, Raquel Delgado-Mederos, Ana Calleja, Juan Carlos Portilla, Ángeles Ortega-Casarrubios, Blanca Fuentes, on behalf of the GLIAS-III study Group Prognostic value of glycemic variability in acute ischemic stroke in the GLycemia In Acute Stroke (GLIAS) III study. Anonymised Dataset. RIMASalud. Version 1.0. 29/07/2026.
  • de Celis-Ruiz, Elena
  • Pastor, Silvia
  • González Pérez de Villar, Noemí
  • Martínez-Balaguer, María
  • Freijo, Marimar
  • Castellanos, Mar
  • Díez-González, Noemí
  • Santamaría, María
  • Amaya-Pascasio, Laura
  • Fraga-Bau, Arturo
  • Delgado-Mederos, Raquel
  • Calleja, Ana
  • Portilla, Juan Carllos
  • Ortega-Casarrubios, Mª Ángeles
  • Fuentes, Blanca
This repository contains the anonymised participant-level dataset generated during the GLIAS-III study, a prospective multicentre observational cohort investigating continuous glucose monitoring (CGM), glycaemic variability and clinical outcomes in patients with acute ischaemic stroke. The dataset is made publicly available to promote transparency, reproducibility and secondary research while ensuring compliance with applicable ethical and data protection regulations., The repository contains the following files: -GLIASIII_dataset.csv: Anonymised participant-level dataset. -GLIASIII_Metadata.pdf: Complete metadata describing study design, methodology, variables, anonymisation procedures and data processing. It includes the Data Dictionary (definitions, coding and units) -GLIASIII_README.txt: General information and instructions for dataset reuse.
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
oai:repositoriosaludmadrid.es:20.500.12530/146681
Datos de investigación Set de datos (Dataset)

Datos relativos al artículo Mitochondrial function of peripheral lymphocytes: role on multiple sclerosis clinical subtypes

  • González-Jiménez, Adela
  • de Heras-Pino, Paloma
  • Moreno-Jerez, Alba
  • Mena-Plaza, Estela
  • Aladro, Yolanda
  • Pilo, Belén
  • Oreja-Guevara, Celia
  • Gómez-Estévez, Irene
  • López-Pastor, Andrea R
  • Gómez-Delgado, Irene
  • Urcelay, Elena
dataset del artículo Mitochondrial function of peripheral lymphocytes: role on multiple sclerosis clinical subtypes y archivo Readme.txt. asociado, AIMS: Multiple sclerosis (MS) is an immune-mediated neurodegenerative disease of unknown etiology, resulting in unmet therapeutic needs. Symptoms heterogeneity and incomplete mechanistic understanding hinder effective patient stratification. We aimed to evaluate the integrated peripheral immune response in established MS clinical subtypes, focusing on differences in mitochondrial function that might validate this stratification and further clarify MS etiology. MATERIALS AND METHODS: Mitochondrial activity of peripheral blood mononuclear cells (PBMCs) upon PHA-stimulation was analysed in MS patients (58 relapsing-remitting (RRMS), 21 secondary progressive (SPMS), and 35 primary progressive (PPMS)) and 35 healthy controls (HC). KEY FINDINGS: In unstimulated conditions, MS patients presented higher mitochondrial ROS (reactive oxygen species) and decreased coupling than HC. Compared with other progressive MS (PMS) subtypes, PBMCs from RRMS presented significantly higher early/late activation and proliferation after PHA stimulation (P = 0.013/P = 0.002, and P = 0.04, respectively), with increased mitochondrial depolarization (P = 0.017). Compared to HC, PHA-stimulated PBMCs from PMS exhibited marked decreases in basal (P = 0.017), maximal, and ATP-linked respiration, increased coupling (P = 0.009), and lower spare respiratory and glycolytic capacities (basal: P = 0.015, maximal: P = 0.064), with parallel decreased GLUT1 expression (P = 0.025). These changes appeared independent of some treatments. SIGNIFICANCE: Upon PHA-stimulation, PMS patients displayed decreased basal, maximal, ATP-linked respiration, and reduced spare respiratory and glycolytic capacities, compared to RRMS and HC, mirroring opposed trends in unstimulated conditions. These findings suggest a severity gradient across MS clinical forms, supporting a disease continuum rather than strictly defined subtypes. The central role of unresolved mitochondrial dysfunction in MS warrants further investigation and may guide novel therapeutic strategies.
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
oai:repositoriosaludmadrid.es:20.500.12530/146656
Datos de investigación Set de datos (Dataset)

THE EFFECT OF GEOGRAPHYC AND CLIMATIC FACTORS ON THE HOSPITALITY BURDEN DUE TO KIDNEY STONES IN SPAIN 1997-2022. DATASET

  • SAENZ-MEDINA, JAVIER
Buscador avanzado